DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, a…
Medical - Devices
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about DexCom, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -0.1000 | -0.015 | 160 | 283 | -29 | -14 | -21 | -2 | -28 | -13 | 84 | 164 |
| 2015 | -0.0745 | -0.070 | 259 | 395 | -22 | -29 | -21 | 64 | -21 | 47 | 128 | 132 |
| 2016 | -0.1800 | -0.197 | 402 | 570 | -57 | -59 | -57 | -44 | -57 | -57 | 198 | 268 |
| 2017 | -0.2000 | -0.153 | 573 | 712 | -65 | -54 | -64 | -12 | -63 | -42 | 286 | 450 |
| 2018 | -0.1500 | -0.022 | 718 | 1,001 | -50 | -41 | -35 | 42 | -42 | -185 | 349 | 732 |
| 2019 | -0.3600 | 0.358 | 1,031 | 1,455 | -127 | 5 | -103 | 243 | -186 | 93 | 432 | 1,153 |
| 2020 | 0.2800 | 0.762 | 1,476 | 1,912 | 101 | 469 | 164 | 335 | 142 | 265 | 515 | 575 |
| 2021 | 1.3100 | 0.707 | 1,926 | 2,448 | 493 | 108 | 382 | 305 | 299 | 199 | 620 | 733 |
| 2022 | 0.4000 | 0.797 | 2,448 | 2,905 | 154 | 212 | 277 | 398 | 265 | 222 | 810 | 1,027 |
| 2023 | 0.8800 | 1.444 | 2,909 | 3,602 | 341 | 541 | 416 | 438 | 391 | 244 | 1,000 | 1,130 |
| 2024 | 1.4000 | 1.703 | 3,622 | 4,016 | 541 | 724 | 916 | 658 | 597 | 486 | 1,185 | 1,344 |
| 2025 | - | 2.029 | - | 4,611 | - | 889 | - | 756 | - | 558 | - | 1,543 |
| 2026 | - | 2.471 | - | 5,323 | - | 2.F12X/td> | - | 2.F121/td> | - | 2.F121 | - | 2.F121 |
| 2027 | - | 3.055 | - | 6,290 | - | 1.F13X/td> | - | 1.F131/td> | - | 1.F131 | - | 1.F131 |
| 2028 | - | 3.704 | - | 7,186 | - | 0.F14X/td> | - | 0.F141/td> | - | 0.F141 | - | 0.F141 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
Overweight
Prev. Grade
Overweight
Nov. 6, 2024
Overweight
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-28.888% $21.51 · MISS
Nov. 6, 2024Price Then
$69.00
Price Target
$95.97
Price Now
$74.46